Cargando…

Network pharmacology and molecular docking-based study on exploring the potential mechanism of Lycium barbarum L: In the treatment of atherosclerosis

BACKGROUND: Goji berries (Lycium barbarum L) are herbal medicine that have a long history of use and multiple pharmacological activities. In this study, we investigated the potential therapeutic effects of Goji berries on atherosclerosis (AS) using network pharmacology and molecular docking. METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales: Qin, Xinchen, Xie, Zikai, Chen, Xi, Wang, Xiaoxuan, Ma, Lijuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10627648/
https://www.ncbi.nlm.nih.gov/pubmed/37932998
http://dx.doi.org/10.1097/MD.0000000000035734
_version_ 1785131566812364800
author Qin, Xinchen
Xie, Zikai
Chen, Xi
Wang, Xiaoxuan
Ma, Lijuan
author_facet Qin, Xinchen
Xie, Zikai
Chen, Xi
Wang, Xiaoxuan
Ma, Lijuan
author_sort Qin, Xinchen
collection PubMed
description BACKGROUND: Goji berries (Lycium barbarum L) are herbal medicine that have a long history of use and multiple pharmacological activities. In this study, we investigated the potential therapeutic effects of Goji berries on atherosclerosis (AS) using network pharmacology and molecular docking. METHODS: The active compounds of Goji berries were identified using the Traditional Chinese Medicine Systems Pharmacology platform, as well as the literature and the targets of each active compound were obtained using the Swiss Target Prediction database. The AS-related targets were collected from the GeneCards and OMIM databases to obtain the common targets of Goji berries and AS. The drug-compound-target-disease network and protein-protein interaction network were constructed using the Cytoscape software to obtain the core target proteins of Goji berries related to AS. Gene ontology analysis of the core targets and Kyoto encyclopedia of genes and genomes pathway enrichment analysis were performed by Metascape. The target-chemical correlations were verified using AutoDock molecular docking. RESULTS: After analysis, 44 active compounds within Goji berries were obtained that exhibit associations with AS. Among these, the proteins exhibiting the highest degrees of interaction within the compound-targeted protein protein-protein interaction network were AKT1, SRC, MAPK3, MAPK1, RELA, and STAT3. The gene ontology-biology process analysis showed that compound-targeted proteins were mainly involved in regulating small molecule metabolic process, cellular response to chemical stress, reactive oxygen species metabolic process, and regulation of inflammatory response. Kyoto encyclopedia of genes and genomes pathway mainly included lipid and AS in which AKT1, SRC, MAPK3, and MAPK1 were involved. Advanced glycation end-product-receptor for advanced glycation end-product signaling pathway in diabetic complications, Chagas disease, and pancreatic disease. Molecular docking assessment showed that fucosterol is bound to AKT1, MAPK3, and SRC. CONCLUSION: This study demonstrates that network pharmacology and molecular docking analyses contribute to a better understanding of Goji berries active compounds and targets as potential therapeutic drugs for treating AS.
format Online
Article
Text
id pubmed-10627648
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-106276482023-11-07 Network pharmacology and molecular docking-based study on exploring the potential mechanism of Lycium barbarum L: In the treatment of atherosclerosis Qin, Xinchen Xie, Zikai Chen, Xi Wang, Xiaoxuan Ma, Lijuan Medicine (Baltimore) 3400 BACKGROUND: Goji berries (Lycium barbarum L) are herbal medicine that have a long history of use and multiple pharmacological activities. In this study, we investigated the potential therapeutic effects of Goji berries on atherosclerosis (AS) using network pharmacology and molecular docking. METHODS: The active compounds of Goji berries were identified using the Traditional Chinese Medicine Systems Pharmacology platform, as well as the literature and the targets of each active compound were obtained using the Swiss Target Prediction database. The AS-related targets were collected from the GeneCards and OMIM databases to obtain the common targets of Goji berries and AS. The drug-compound-target-disease network and protein-protein interaction network were constructed using the Cytoscape software to obtain the core target proteins of Goji berries related to AS. Gene ontology analysis of the core targets and Kyoto encyclopedia of genes and genomes pathway enrichment analysis were performed by Metascape. The target-chemical correlations were verified using AutoDock molecular docking. RESULTS: After analysis, 44 active compounds within Goji berries were obtained that exhibit associations with AS. Among these, the proteins exhibiting the highest degrees of interaction within the compound-targeted protein protein-protein interaction network were AKT1, SRC, MAPK3, MAPK1, RELA, and STAT3. The gene ontology-biology process analysis showed that compound-targeted proteins were mainly involved in regulating small molecule metabolic process, cellular response to chemical stress, reactive oxygen species metabolic process, and regulation of inflammatory response. Kyoto encyclopedia of genes and genomes pathway mainly included lipid and AS in which AKT1, SRC, MAPK3, and MAPK1 were involved. Advanced glycation end-product-receptor for advanced glycation end-product signaling pathway in diabetic complications, Chagas disease, and pancreatic disease. Molecular docking assessment showed that fucosterol is bound to AKT1, MAPK3, and SRC. CONCLUSION: This study demonstrates that network pharmacology and molecular docking analyses contribute to a better understanding of Goji berries active compounds and targets as potential therapeutic drugs for treating AS. Lippincott Williams & Wilkins 2023-11-03 /pmc/articles/PMC10627648/ /pubmed/37932998 http://dx.doi.org/10.1097/MD.0000000000035734 Text en Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle 3400
Qin, Xinchen
Xie, Zikai
Chen, Xi
Wang, Xiaoxuan
Ma, Lijuan
Network pharmacology and molecular docking-based study on exploring the potential mechanism of Lycium barbarum L: In the treatment of atherosclerosis
title Network pharmacology and molecular docking-based study on exploring the potential mechanism of Lycium barbarum L: In the treatment of atherosclerosis
title_full Network pharmacology and molecular docking-based study on exploring the potential mechanism of Lycium barbarum L: In the treatment of atherosclerosis
title_fullStr Network pharmacology and molecular docking-based study on exploring the potential mechanism of Lycium barbarum L: In the treatment of atherosclerosis
title_full_unstemmed Network pharmacology and molecular docking-based study on exploring the potential mechanism of Lycium barbarum L: In the treatment of atherosclerosis
title_short Network pharmacology and molecular docking-based study on exploring the potential mechanism of Lycium barbarum L: In the treatment of atherosclerosis
title_sort network pharmacology and molecular docking-based study on exploring the potential mechanism of lycium barbarum l: in the treatment of atherosclerosis
topic 3400
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10627648/
https://www.ncbi.nlm.nih.gov/pubmed/37932998
http://dx.doi.org/10.1097/MD.0000000000035734
work_keys_str_mv AT qinxinchen networkpharmacologyandmoleculardockingbasedstudyonexploringthepotentialmechanismoflyciumbarbarumlinthetreatmentofatherosclerosis
AT xiezikai networkpharmacologyandmoleculardockingbasedstudyonexploringthepotentialmechanismoflyciumbarbarumlinthetreatmentofatherosclerosis
AT chenxi networkpharmacologyandmoleculardockingbasedstudyonexploringthepotentialmechanismoflyciumbarbarumlinthetreatmentofatherosclerosis
AT wangxiaoxuan networkpharmacologyandmoleculardockingbasedstudyonexploringthepotentialmechanismoflyciumbarbarumlinthetreatmentofatherosclerosis
AT malijuan networkpharmacologyandmoleculardockingbasedstudyonexploringthepotentialmechanismoflyciumbarbarumlinthetreatmentofatherosclerosis